You are here

  • Home
  • Archive
  • Volume 78, Issue 3
  • Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Article metrics

Article menu

Download PDFPDF

XML
Osteoarthritis
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

 

Online download statistics by month:

Online download statistics by month: December 2018 to March 2024

AbstractFullPdf
Dec 2018930956149
Jan 201947552376
Feb 2019521509101
Mar 201926025885
Apr 201914313439
May 201912411776
Jun 201911411055
Jul 201910610153
Aug 2019636121
Sep 2019616017
Oct 2019757114
Nov 2019706524
Dec 2019838037
Jan 2020847938
Feb 2020817626
Mar 2020767322
Apr 2020676655
May 2020837476
Jun 2020656421
Jul 2020585322
Aug 2020565325
Sep 202049409
Oct 2020867950
Nov 2020817236
Dec 2020655617
Jan 2021787224
Feb 2021625920
Mar 2021534917
Apr 2021494722
May 2021535319
Jun 2021564625
Jul 2021544628
Aug 2021504524
Sep 2021524617
Oct 2021696450
Nov 2021736745
Dec 202111311024
Jan 202262558
Feb 2022494516
Mar 2022857727
Apr 2022766828
May 2022989333
Jun 2022817728
Jul 2022686210
Aug 202210610524
Sep 2022787522
Oct 2022575511
Nov 2022614922
Dec 2022373614
Jan 2023595515
Feb 2023817131
Mar 2023928637
Apr 2023383223
May 2023393328
Jun 2023534711
Jul 2023312718
Aug 2023585328
Sep 2023979325
Oct 202321721126
Nov 202335033135
Dec 202311010721
Jan 2024997779
Feb 2024816329
Mar 20249992118
Total700067092226